Plexiform neurolymphomatosis

Rev Neurol (Paris). 2016 Apr-May;172(4-5):328-30. doi: 10.1016/j.neurol.2016.02.008. Epub 2016 Apr 23.

Authors

R Denays¹, V Baudrez², P Abouhamad³, T Derème³, G Milbouw⁴, J-P Hermanne⁵

Affiliations

¹ Department of Neurology, CHR Sambre & Meuse, avenue Albert Ier 185, 5000 Namur, Belgium. Electronic address: [email protected].
² Department of Radiology, CHR Sambre & Meuse, avenue Albert Ier 185, 5000 Namur, Belgium.
³ Department of Nuclear Medicine, CHR Sambre & Meuse, avenue Albert Ier 185, 5000 Namur, Belgium.
⁴ Department of Neurosurgery, CHR Sambre & Meuse, avenue Albert Ier 185, 5000 Namur, Belgium.
⁵ Department of Hemato-Oncology, CHR Sambre & Meuse, avenue Albert Ier 185, 5000 Namur, Belgium.

PMID: 27117434
DOI: 10.1016/j.neurol.2016.02.008

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Animals
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cyclophosphamide / therapeutic use
Doxorubicin / therapeutic use
Female
Fluorodeoxyglucose F18
Humans
Leukemic Infiltration / diagnostic imaging
Leukemic Infiltration / drug therapy
Leukemic Infiltration / pathology*
Lymphoma, B-Cell / diagnostic imaging
Lymphoma, B-Cell / drug therapy
Lymphoma, B-Cell / pathology*
Paraneoplastic Syndromes, Nervous System / diagnostic imaging
Paraneoplastic Syndromes, Nervous System / drug therapy
Paraneoplastic Syndromes, Nervous System / pathology*
Positron Emission Tomography Computed Tomography
Prednisone / therapeutic use
Rituximab
Vincristine / therapeutic use

Substances

Antibodies, Monoclonal, Murine-Derived
R-CHOP protocol
Fluorodeoxyglucose F18
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone